CIK 0001231457
- Non-accelerated filer
- Smaller reporting company
- Emerging growth company
GENELUX Corp
Sign in to watch- Ticker
- GNLX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- Phone
- +1 805-267-9889
- Business address
- 2625 TOWNSGATE ROAD, SUITE 230, WESTLAKE VILLAGE, CA, 91361
- 4 Open-market sale VP, Clinical Trial Operations sold 3,265 shares at $23.73 ($77,478)
- 4 Open-market sale President and CEO sold 8,349 shares at $23.73 ($198,122)
- 3 Insider Initial Statement of Ownership
- 3 Insider Initial Statement of Ownership
- 4 Grant or award Director acquired 9,000 shares (grant or award)
- 4 Grant or award Director acquired 1,000 shares (grant or award)
- 4 Grant or award Director acquired 1,000 shares (grant or award)
- 4 Grant or award Director acquired 9,000 shares (grant or award)
- 4 Grant or award President and CEO acquired 23,000 shares (grant or award)
- 4 Grant or award Associate VP, Research acquired 6,000 shares (grant or award)
- 4 Grant or award General Counsel acquired 900 shares (grant or award)
- 4 Grant or award Chief Financial Officer acquired 3,600 shares (grant or award)
- 4 Grant or award VP, Clinical Trial Operations acquired 9,000 shares (grant or award)
- 4 Grant or award VP, Pharmaceutical Development acquired 9,000 shares (grant or award)
- 4 Open-market buy Associate VP, Research bought 200 shares at $6.25 ($1,250)
- 4 Conversion 10% owner acquired 1,000,000 shares (conversion)
- 4 Conversion Director acquired 470,000 shares (conversion)
- 4 Conversion Director acquired 11,362 shares (conversion)
- 3 Insider Initial Statement of Ownership
- 3 Insider Initial Statement of Ownership
Page 9 of 10 · 190 filings